ArticleToxicology reports2025
Mitigating renal dysfunction in liver cirrhosis: Therapeutic role of ferrous sulphate, folic acid, and its co-administration.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synthesis, characterisation, computational study, amelioration of ruthenium kesar nanoparticle, antioxidant and glycolytic enzyme activity alterations in cirrhotic liver extract.Scientific reports · 2026Article
- The bidirectional relationship between diabetes mellitus and liver disease: Mechanisms, clinical implications, and management strategies.Endocrine · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver and kidneys are vital organs for detoxification and metabolic regulation. Regular consumption of alcohol and acetaminophen can cause liver cirrhosis. Cirrhosis increases oxidative stress in kidneys by disrupting the balance between reactive oxygen species (ROS) and antioxidants, leading to cell damage. Folic acid and ferrous sulfate are two anti-anemic drugs treat various diseases, have a high reactive oxygen radical quenching ability, resulting in protection against oxidative damage in aerobic cell. The aim of this study was to investigate mitigating renal dysfunction in liver cirrhosis and therapeutic potential effect of ferrous sulfate, folic acid and its co-administration caused by alcohol-acetaminophen induced liver cirrhosis. Animals were divided into six groups. Rats of normal control group received water and normal diet ad libitum; AC and LC group received 4.5 % alcohol and a combination of 4.5 % alcohol and acetaminophen (300 mg/kg bw) via drinking water respectively for seven days. After seven days, rats of LC+FS, LC+FA and LC+FS+FA received FS (5 mg/kg bw), FA (5 mg/kg bw) and FS+FA (5 mg/kg bw) respectively via drinking water for four weeks. Enzyme activity and protein expression were measured by semi-quantitative RT PCR and western blotting respectively. Results revealed that FS and FA treatment individually and together restored the antioxidant enzyme activity and the levels of glycolytic pathway towards normal which were affected due to liver cirrhosis. FS and FA are well known anti-anemic drugs and proved to be efficient agents for antioxidant and glycolytic enzymes alteration in liver cirrhosis. This novel approach could lead to new treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.